 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Johnson & Johnson Seeks Full FDA Approval for HIV TreatmentFebruary 13, 2009 Johnson & Johnson's Tibotec unit is requesting full Food and Drug Administration approval of its HIV drug Intelence, a non-nucleoside reverse transcriptase inhibitor designed for patients who have stopped responding to other treatments. FDA in January gave the drug preliminary approval under its accelerated approval program, allowing the company to market Intelence. In order to gain full approval, FDA required Tibotec to supply follow-up data on the drug's effectiveness. According to data submitted by Tibotec, 60 percent of patients taking Intelence for four months had undetectable HIV levels in their blood, compared with 39 percent of patients taking a placebo. Associated Press 02.05.2009  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
